drugset / Trial / NCT00522925

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925

Phase 2 Completed 280 enrolled Ligand Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.

Timeline

Start
2007-08
Primary completion
2008-04
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sparsentan Small molecule 200 mg
Subject Sparsentan Small molecule 500 mg

Indications